Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$17.66 USD

17.66
1,533,637

+0.46 (2.67%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $17.67 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth

Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.

Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal

Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.

Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

HRMY or ACAD: Which Is the Better Value Stock Right Now?

HRMY vs. ACAD: Which Stock Is the Better Value Option?

Ultragenyx (RARE) Posts Update From AS Study of GTX-102

Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.